It is estimated that 224,390 new cases of lung cancer will be diagnosed in 2016 in USA, making it the second most incident cancer for all genders, only behind breast cancer. Additionally, lung cancer will be first cause of cancer death in USA during this year, causing 150,080 estimated deaths. In this commentary, published in Lung Cancer Management, Denis L Jardim and Debora de Melo Gagliato discuss recent results of immunotherapy for the indication of non-small-cell lung carcinoma.
Access the paper through
Jardim DL, de Melo Gagliato D. Recent results of immunotherapy and perspectives for advanced NSCLC. Lung Cancer Manag. 5(2), 57–60 (2016)